Leukemia associated mutant Wilms’ tumor gene 1 protein promotes expansion of human hematopoietic progenitor cells

Lee, 2001, Wilms tumor and the WT1 gene, Exp Cell Res, 264, 74, 10.1006/excr.2000.5131 Fraizer, 1995, Expression of the tumor suppressor gene WT1 in both human and mouse bone marrow, Blood, 86, 4704, 10.1182/blood.V86.12.4704.bloodjournal86124704 Maurer, 1997, The Wilms’ tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro, Exp Hematol, 25, 945 Baird, 1997, Expression of the Wilms’ tumor gene (WT1) in normal hemopoiesis, Exp Hematol, 25, 312 King-Underwood, 2005, Wt1 is not essential for hematopoiesis in the mouse, Leuk Res, 29, 803, 10.1016/j.leukres.2004.11.020 Alberta, 2003, Role of the WT1 tumor suppressor in murine hematopoiesis, Blood, 101, 2570, 10.1182/blood-2002-06-1656 Chau, 2011, Acute multiple organ failure in adult mice deleted for the developmental regulator Wt1, PLoS Genet, 7, e1002404, 10.1371/journal.pgen.1002404 Yang, 2007, A tumor suppressor and oncogene: the WT1 story, Leukemia, 21, 868, 10.1038/sj.leu.2404624 Algar, 2002, A review of the Wilms’ tumor 1 gene (WT1) and its role in hematopoiesis and leukemia, J Hematother Stem Cell Res, 11, 589, 10.1089/15258160260194749 Pritchard-Jones, 1994, The Wilms tumour (WT1) gene is mutated in a secondary leukaemia in a WAGR patient, Hum Mol Genet, 3, 1633, 10.1093/hmg/3.9.1633 King-Underwood, 1996, Mutations in the Wilms’ tumor gene WT1 in leukemias, Blood, 87, 2171, 10.1182/blood.V87.6.2171.bloodjournal8762171 King-Underwood, 1998, Wilms’ tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance, Blood, 91, 2961, 10.1182/blood.V91.8.2961.2961_2961_2968 Renneville, 2009, Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association, Cancer, 115, 3719, 10.1002/cncr.24442 Virappane, 2008, Mutation of the Wilms’ tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party, J Clin Oncol, 26, 5429, 10.1200/JCO.2008.16.0333 Summers, 2007, Wilms’ tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML, Leukemia, 21, 550, 10.1038/sj.leu.2404514 Paschka, 2008, Wilms’ tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study, J Clin Oncol, 26, 4595, 10.1200/JCO.2007.15.2058 Gaidzik, 2009, Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German–Austrian AML Study Group, Blood, 113, 4505, 10.1182/blood-2008-10-183392 Becker, 2010, Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study, Blood, 116, 788, 10.1182/blood-2010-01-262543 Hollink, 2009, Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia, Blood, 113, 5951, 10.1182/blood-2008-09-177949 Owen, 2010, The clinical relevance of Wilms Tumour 1 (WT1) gene mutations in acute leukaemia, Hematol Oncol, 28, 13 Miyagawa, 1999, Mutations of the WT1 gene in childhood nonlymphoid hematological malignancies, Genes Chromosomes Cancer, 25, 176, 10.1002/(SICI)1098-2264(199906)25:2<176::AID-GCC14>3.0.CO;2-F Ho, 2010, Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group, Blood, 116, 702, 10.1182/blood-2010-02-268953 Willasch, 2009, Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study, Leukemia, 23, 1472, 10.1038/leu.2009.51 Svensson, 2005, DNA-binding dependent and independent functions of WT1 protein during human hematopoiesis, Exp Cell Res, 308, 211, 10.1016/j.yexcr.2005.04.018 Tajinda, 1999, Regulation of insulin-like growth factor I receptor promoter activity by wild-type and mutant versions of the WT1 tumor suppressor, Endocrinology, 140, 4713, 10.1210/endo.140.10.7065 Svensson, 2007, The Wilms’ tumor gene 1 (WT1) induces expression of the N-myc downstream regulated gene 2 (NDRG2), DNA Cell Biol, 26, 589, 10.1089/dna.2007.0586 Ginzinger, 2002, Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream, Exp Hematol, 30, 503, 10.1016/S0301-472X(02)00806-8 Olsson, 2010, Increased levels of cell-free hemoglobin, oxidation markers, and the antioxidative heme scavenger alpha(1)-microglobulin in preeclampsia, Free Radical Biol Med, 48, 284, 10.1016/j.freeradbiomed.2009.10.052 Tusher, 2001, Significance analysis of microarrays applied to the ionizing radiation response, Proc Natl Acad Sci U S A, 98, 5116, 10.1073/pnas.091062498 Nilsson, 2007, Threshold-free high-power methods for the ontological analysis of genome-wide gene-expression studies, Genome Biol, 8, R74, 10.1186/gb-2007-8-5-r74 Novershtern, 2011, Densely interconnected transcriptional circuits control cell states in human hematopoiesis, Cell, 144, 296, 10.1016/j.cell.2011.01.004 Smyth, 2004, Linear models and empirical bayes methods for assessing differential expression in microarray experiments, Statistical Appl Genet Mol Biol, 3, Article 3, 10.2202/1544-6115.1027 Team RC. R: a language and environment for statistical computing; 2013. http://www.R-project.org/. Bates DM, Maechler M, Bolker B. Ime4: linear mixed-effects models using S4 classes. R package version 0.999999-0; 2012. http://CRAN.R-project.org/package=Ime4. Hothorn, 2008, Simultaneous inference in general parametric models, Biometrical J Biometrische Zeitschrift, 50, 346, 10.1002/bimj.200810425 Richmond, 2005, Turning cells red: signal transduction mediated by erythropoietin, Trends Cell Biol, 15, 146, 10.1016/j.tcb.2005.01.007 Grebien, 2008, Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2, Blood, 111, 4511, 10.1182/blood-2007-07-102848 Ferbeyre, 2011, The role of Stat5 transcription factors as tumor suppressors or oncogenes, Biochim Biophys Acta - Rev Cancer, 1815, 104, 10.1016/j.bbcan.2010.10.004 Kirschner, 2008, The Wilms’ tumor suppressor Wt1 activates transcription of the erythropoietin receptor in hematopoietic progenitor cells, FASEB J, 22, 2690, 10.1096/fj.07-097576 Nishida, 2006, AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1, Blood, 107, 3303, 10.1182/blood-2005-04-1656 Ihle, 1995, Jaks and Stats in signaling by the cytokine receptor superfamily, Trends Genet, 11, 69, 10.1016/S0168-9525(00)89000-9 Benekli, 2003, Signal transducer and activator of transcription proteins in leukemias, Blood, 101, 2940, 10.1182/blood-2002-04-1204